---
title: "Daxor Corporation (DXR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/DXR.US.md"
symbol: "DXR.US"
name: "Daxor Corporation"
industry: "Health Care Equipment"
---

# Daxor Corporation (DXR.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [www.daxor.com](https://www.daxor.com) |

## Company Profile

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was for...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: C (0.56)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 86 / 185 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -57.00% |  |
| Net Profit YoY | 6.55% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.01 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 71.73M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 66306.00 |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.26% | C |
| Profit Margin | 2710.84% | A |
| Gross Margin | 100.00% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -57.00% | E |
| Net Profit YoY | 6.55% | C |
| Total Assets YoY | 4.44% | C |
| Net Assets YoY | 9.10% | B |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 3.69% | C |
| OCF YoY | -57.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 0.76% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Daxor Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.26%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2710.84%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-57.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "6.55%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.44%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.10%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "3.69%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-57.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "0.76%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | A | A | A | A |
| 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 04 | Stryker (US.SYK) | A | B | C | C | B | B |
| 05 | Boston Scientific (US.BSX) | B | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 39.58 | 28/181 | 84.66 | 40.90 | 35.29 |
| PB | 2.00 | 55/181 | 1.83 | 1.50 | 1.11 |
| PS (TTM) | 1073.06 | 147/181 | 984.77 | 455.96 | 329.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-11T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 50% |
| Overweight | 1 | 50% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.21 |
| Highest Target | 22.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/DXR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/DXR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/DXR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.